Orelabrutinib Maintenance Therapy After ASCT in Primary Central Nervous System Lymphoma
NCT05334238
·
clinicaltrials.gov ↗
PHASE3
Phase
UNKNOWN
Status
174
Enrollment
OTHER
Sponsor class
Conditions
Primary Central Nervous System Lymphoma
Interventions
DRUG:
Orelabrutinib
Sponsor
Ruijin Hospital